ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Fabiola Cervantes-Gomez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.